Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Cinclus Pharma
Deal Size : $249.2 million
Deal Type : Licensing Agreement
Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe
Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $14.7 million
May 22, 2025
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Cinclus Pharma
Deal Size : $249.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Generic HIV raltegravir medicines approved
Details : Raltegravir is an approved, small molecule, HIV-1 integrase inhibitor, available as a film coated tablet for the treatment of HIV in adult and paediatric patients weighing at least 40kg.
Product Name : Raltegravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Lupin Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Biocon
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon to Obtain Approval for Diabetes Drug, Liraglutide in UK
Details : Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Product Name : Liraglutide-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Biocon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Convenient Treatment Option for Thromboembolic Events
Details : Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.
Product Name : Rivaroxaban-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Recipient : Adalvo
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Recipient : Adalvo
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Tillomed Laboratories Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Zentiva Completes Major Product Acquisition from Tillomed Spain
Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Tillomed Laboratories Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omeprazole magnesium is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid...
Product Name : Omeprazole Magnesium-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2022
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
Biocon Limited Enters Into a Commercialization Agreement With Zentiva in Europe
Details : Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.
Product Name : Liraglutide-Generic
Product Type : Peptide
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development
Details : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.
Product Name : Sitagliptin Phosphate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zent2U announces Completion of Bioequivalence Trials on Sertraline
Details : Sertraline hydrochloride potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). It is indicated for the treatment of MDD, PTSD, PMDD, panic disorder, and social anxiety disorder.
Product Name : Sertraline Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2021
Lead Product(s) : Sertraline Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable